AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11889328 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide (250 microg)
Number of subjects: 55
Study 11889328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol plus ipratropium bromide
Number of subjects: 55
Study 9620490 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadexomer iodine paste (Iodosorb/Iodoflex)
Number of subjects: 153
Study 9620490 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressing (Duoderm E, Granuflex E)
Number of subjects: 153
Study 9620490 — intervention group
Group type: COMPARATOR
Intervention: Paraffin gauze dressing (Jelonet)
Number of subjects: 153
Study 2654196 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital subtraction images
Number of subjects: 62
Study 2654196 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast enhanced subtraction images
Number of subjects: 62
Study 2654196 — intervention group
Group type: EXPERIMENTAL
Intervention: Color-converted digital subtraction images
Number of subjects: 62
Study 2654196 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-analysis after 2 months
Number of subjects: 62
Study 201006 — intervention group
Group type: EXPERIMENTAL
Intervention: RMP (Rifampicin)
Number of subjects: 114
Study 201006 — intervention group
Group type: EXPERIMENTAL
Intervention: EMB (Ethambutol)
Number of subjects: 114
Study 201006 — intervention group
Group type: EXPERIMENTAL
Intervention: SM (Streptomycin)
Number of subjects: 114
Study 201006 — intervention group
Group type: EXPERIMENTAL
Intervention: INH-RMP (Isoniazid and Rifampicin)
Number of subjects: 114
Study 201006 — intervention group
Group type: EXPERIMENTAL
Intervention: INH-EMB (Isoniazid and Ethambutol)
Number of subjects: 114
Study 201006 — intervention group
Group type: EXPERIMENTAL
Intervention: INH-SM (Isoniazid and Streptomycin)
Number of subjects: 114
Study 6452798 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 40
Study 6452798 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 40
Study 31686770 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth screening procedure every third month (3M)
Number of subjects: 102
Study 31686770 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth screening procedure on demand (OD)
Number of subjects: 102
Study 31686770 — intervention group
Group type: COMPARATOR
Intervention: eHealth screening procedure (3M)
Number of subjects: 102
Study 31686770 — intervention group
Group type: COMPARATOR
Intervention: eHealth screening procedure (OD)
Number of subjects: 102
Study 28076829 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg once daily + Cabergoline 0.5mg/week for 12 weeks
Number of subjects: 88
Study 28076829 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone for 12 weeks
Number of subjects: 88
Study 27701629 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Conversational Recast treatment (30-min session, massed condition)
Number of subjects: 16
Study 27701629 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Conversational Recast treatment (3 sessions of 10-min each, spaced condition)
Number of subjects: 16
Study 27701629 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Conversational Recast treatment (both conditions)
Number of subjects: 16
Study 24201413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol (Group A)
Number of subjects: 150
Study 24201413 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 150
Study 22494344 — intervention group
Group type: EXPERIMENTAL
Intervention: Explanations provided for the events in the decision task
Number of subjects: 0
Study 22494344 — intervention group
Group type: COMPARATOR
Intervention: No explanation provided for the events in the decision task
Number of subjects: 0
Study 19122076 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lumbar plexus block with patient-controlled analgesia
Number of subjects: 225
Study 19122076 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral block with patient-controlled analgesia
Number of subjects: 225
Study 19122076 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia alone
Number of subjects: 225
Study 17599881 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative reperfusion technique (group II); pressure of 20 to 25 mmHg for 2 minutes, then increased to 40 mmHg for another 2 minutes.
Number of subjects: 57
Study 17599881 — intervention group
Group type: COMPARATOR
Intervention: Standard techniques (group I); no specific intervention details provided.
Number of subjects: 57
Study 14691442 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual and prolonged balloon angioplasty (GPBA)
Number of subjects: 263
Study 14691442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty (CBA)
Number of subjects: 263
Study 14691442 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (POBA)
Number of subjects: 263
Study 11944007 — intervention group
Group type: COMPARATOR
Intervention: Saline (Sal)
Number of subjects: 25
Study 11944007 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelofusine (Gel)
Number of subjects: 25
Study 11944007 — intervention group
Group type: EXPERIMENTAL
Intervention: Levovist (Lev)
Number of subjects: 25
Study 11944007 — intervention group
Group type: COMPARATOR
Intervention: Gel vs Sal
Number of subjects: 25
Study 9805323 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal span tasks
Number of subjects: 2
Study 9805323 — intervention group
Group type: EXPERIMENTAL
Intervention: Recency effect with visually and auditory presented lists
Number of subjects: 2
Study 9805323 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory span tasks
Number of subjects: 2
Study 9805323 — intervention group
Group type: EXPERIMENTAL
Intervention: Recency and span measures
Number of subjects: 2
Study 7695302 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 0
Study 7695302 — intervention group
Group type: COMPARATOR
Intervention: Oral co-trimoxazole plus topical fusidic acid
Number of subjects: 0
Study 2636671 — intervention group
Group type: EXPERIMENTAL
Intervention: New essential amino acid formulation (BS695), enriched with valine and threonine, low in phenylalanine and methionine, 3.65 g of nitrogen, i.v. three times per week for six months.
Number of subjects: 21
Study 2636671 — intervention group
Group type: COMPARATOR
Intervention: Standard amino acid solution (control group), 3.65 g of nitrogen, i.v. three times per week for six months.
Number of subjects: 21
Study 336670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate (1,600 mg/day in fractional doses)
Number of subjects: 58
Study 336670 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical-appearing capsules)
Number of subjects: 58
Study 30788692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app-based small-group intervention
Number of subjects: 91
Study 30788692 — intervention group
Group type: COMPARATOR
Intervention: Individual control condition
Number of subjects: 91
Study 30788692 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (small-group and control)
Number of subjects: 91
Study 28448174 — intervention group
Group type: EXPERIMENTAL
Intervention: Social marketing intervention (peer-led strategy)
Number of subjects: 393
Study 28448174 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 393
Study 24978063 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel
Number of subjects: 264
Study 24978063 — intervention group
Group type: COMPARATOR
Intervention: LMA-supreme
Number of subjects: 264
Study 25108576 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (4 capsules daily, 1.01 g EPA + 0.67 g DHA)
Number of subjects: 108
Study 25108576 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (placebo)
Number of subjects: 108
Study 22189085 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oxygen modified atmosphere packaging (HiOx-MAP)
Number of subjects: 36
Study 22189085 — intervention group
Group type: COMPARATOR
Intervention: PVC-overwrapping
Number of subjects: 36
Study 22189085 — intervention group
Group type: EXPERIMENTAL
Intervention: Old season (OS) lambs
Number of subjects: 36
Study 22189085 — intervention group
Group type: EXPERIMENTAL
Intervention: New season (NS) lambs
Number of subjects: 36
Study 19295240 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatically modified isoquercitrin (EMIQ) 100 mg, two capsules daily for 8 weeks
Number of subjects: 20
Study 19295240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18080048 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (10 Hz, 100% resting motor threshold, 2 s on, 60 s off, 300 pulses total)
Number of subjects: 20
Study 18080048 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 20
Study 15208005 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 Index > or = 8%
Number of subjects: 0
Study 15208005 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 Index < or = 4%
Number of subjects: 0
Study 12043313 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic viral C hepatitis patients with steatosis
Number of subjects: 38
Study 12043313 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study 12043313 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic liver steatosis
Number of subjects: 38
Study 12043313 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic viral C hepatitis patients without steatosis
Number of subjects: 38
Study 10378358 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 0
Study 10378358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7639006 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus-preserving gastrectomy (PPG)
Number of subjects: 35
Study 7639006 — intervention group
Group type: COMPARATOR
Intervention: Conventional distal gastrectomy (CDG)
Number of subjects: 35
Study 2487550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine
Number of subjects: 103
Study 2487550 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide/amiloride (diuretic therapy)
Number of subjects: 103
Study 711931 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 12
Study 711931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31508796 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored group (BIS monitoring)
Number of subjects: 100
Study 31508796 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (no BIS monitoring)
Number of subjects: 100
Study 28556418 — intervention group
Group type: EXPERIMENTAL
Intervention: KHK4083 1.0 mg/kg SC
Number of subjects: 55
Study 28556418 — intervention group
Group type: EXPERIMENTAL
Intervention: KHK4083 0.03, 0.1, 0.3, 1.0, 3.0, and 10 mg/kg IV
Number of subjects: 55
Study 28556418 — intervention group
Group type: COMPARATOR
Intervention: KHK4083 (various doses)
Number of subjects: 55
Study 25584800 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochloroacetic acid (MCA) for common warts
Number of subjects: 415
Study 25584800 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy for common warts
Number of subjects: 415
Study 25584800 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochloroacetic acid (MCA) for plantar warts
Number of subjects: 415
Study 25584800 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy combined with salicylic acid (SA) for plantar warts
Number of subjects: 415
Study 24908572 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band imaging (Group 1)
Number of subjects: 237
Study 24908572 — intervention group
Group type: COMPARATOR
Intervention: High definition white light colonoscopy (Group 2)
Number of subjects: 237
Study 21720421 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI/low protein
Number of subjects: 16
Study 21720421 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI/high protein
Number of subjects: 16
Study 21720421 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI/low protein
Number of subjects: 16
Study 21720421 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI/high protein
Number of subjects: 16
Study 21720421 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 19726373 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone + Metoprolol
Number of subjects: 110
Study 19726373 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 110
Study 19726373 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 110
Study 17200314 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARITE Artificial Disc
Number of subjects: 276
Study 17200314 — intervention group
Group type: COMPARATOR
Intervention: Control group (anterior interbody arthrodesis)
Number of subjects: 276
Study 15543222 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance
Number of subjects: 307
Study 15543222 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 307
Study 11524309 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 72
Study 11524309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 9576302 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (low dose, < or =20 mg per day)
Number of subjects: 132
Study 9576302 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (low dose)
Number of subjects: 132
Study 7955241 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG in Group 1 (1970 to 1980)
Number of subjects: 201
Study 7955241 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG in Group 2 (1981 to 1991)
Number of subjects: 201
Study 7955241 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (1970 to 1980)
Number of subjects: 201
Study 7955241 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (1981 to 1991)
Number of subjects: 201
Study 2959438 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin therapy
Number of subjects: 15
Study 2959438 — intervention group
Group type: EXPERIMENTAL
Intervention: ultralente insulin
Number of subjects: 15
Study 2959438 — intervention group
Group type: EXPERIMENTAL
Intervention: ultralente insulin alone
Number of subjects: 15
Study 2959438 — intervention group
Group type: EXPERIMENTAL
Intervention: ultralente and soluble insulin
Number of subjects: 15
Study 30526582 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaya fortified porridge (300 ml daily)
Number of subjects: 326
Study 30526582 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg one-time dosage)
Number of subjects: 326
Study 30526582 — intervention group
Group type: COMPARATOR
Intervention: Plain porridge (control group)
Number of subjects: 326
Study 27052694 — intervention group
Group type: EXPERIMENTAL
Intervention: Hark app
Number of subjects: 22
Study 27052694 — intervention group
Group type: COMPARATOR
Intervention: Pager
Number of subjects: 22
Study 25239451 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical propolis
Number of subjects: 24
Study 25239451 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 22508204 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin 0.03 IU/min for 60 min after cardiopulmonary bypass (CPB)
Number of subjects: 20
Study 22508204 — intervention group
Group type: COMPARATOR
Intervention: Normal saline in equal volume for 60 min after cardiopulmonary bypass (CPB)
Number of subjects: 20
Study 19841932 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine supplementation (4.8 g/day for 4 weeks)
Number of subjects: 14
Study 19841932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18390439 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium fumarate tablets
Number of subjects: 12
Study 18390439 — intervention group
Group type: COMPARATOR
Intervention: Calcium gluconate tablets
Number of subjects: 12
Study 16583594 — intervention group
Group type: EXPERIMENTAL
Intervention: meridol toothbrush
Number of subjects: 68
Study 16583594 — intervention group
Group type: COMPARATOR
Intervention: standard ADA reference toothbrush
Number of subjects: 68
Study 11811565 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene HCl (120 mg)
Number of subjects: 65
Study 11811565 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene HCl (60 mg)
Number of subjects: 65
Study 11811565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 9892858 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (0.2 microgram/kg body weight)
Number of subjects: 24
Study 9892858 — intervention group
Group type: COMPARATOR
Intervention: Low doses of alcohol (BAC 0.03%)
Number of subjects: 24
Study 7735607 — intervention group
Group type: EXPERIMENTAL
Intervention: 77 ppb HONO
Number of subjects: 15
Study 7735607 — intervention group
Group type: EXPERIMENTAL
Intervention: 395 ppb HONO
Number of subjects: 15
Study 7735607 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 15
Study 7735607 — intervention group
Group type: EXPERIMENTAL
Intervention: HONO exposure
Number of subjects: 15
Study 1447397 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetics (n=28)
Number of subjects: 200
Study 1447397 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetics (n=172)
Number of subjects: 200
Study 1447397 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall diabetics (n=200)
Number of subjects: 200
Study 1447397 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=200)
Number of subjects: 200
Study 1447397 — intervention group
Group type: COMPARATOR
Intervention: Type 1 diabetics (n=28) vs Control group (n=200)
Number of subjects: 200
Study 3514193 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic growth hormone (methionyl-hGH) administered to group I (32 children) with high ECP content
Number of subjects: 55
Study 3514193 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic growth hormone (methionyl-hGH) administered to group II (12 children) with reduced ECP content
Number of subjects: 55
Study 3514193 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic growth hormone (methionyl-hGH) administered to group III (11 children) with almost ECP-free preparations
Number of subjects: 55
Study 3514193 — intervention group
Group type: EXPERIMENTAL
Intervention: High antibody titres against ECP and hGH in group I
Number of subjects: 55
Study 3514193 — intervention group
Group type: EXPERIMENTAL
Intervention: A boy with allergy in group I
Number of subjects: 55
Study 29064599 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 0
Study 27126621 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tri-endoscopic group (29 patients)
Number of subjects: 53
Study 27126621 — intervention group
Group type: COMPARATOR
Intervention: Control group (24 patients)
Number of subjects: 53
Study 26389639 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-methylphenidate
Number of subjects: 303
Study 26389639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 23219629 — intervention group
Group type: EXPERIMENTAL
Intervention: PhysioDirect telephone assessment and advice service
Number of subjects: 350000
Study 21978241 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyostimulation superimposed over voluntary contraction (EVG)
Number of subjects: 40
Study 21978241 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study 18452433 — intervention group
Group type: EXPERIMENTAL
Intervention: Asiaticoside-containing cream applied twice a day for 12 weeks
Number of subjects: 27
Study 18452433 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control cream applied to the other eye
Number of subjects: 27
Study 16688996 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymatrine (Oxy)
Number of subjects: 110
Study 16688996 — intervention group
Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 110
Study 12713209 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week summer day camp + 8-week home Internet intervention
Number of subjects: 35
Study 12713209 — intervention group
Group type: COMPARATOR
Intervention: Control group (different 4-week summer day camp + monthly home Internet intervention)
Number of subjects: 35
Study 10636973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling aimed to reach a dietary fat ratio of unsaturated to saturated fat of 2:1 within a total fat intake of 30% to 35% of energy (E%)
Number of subjects: 813
Study 10636973 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 813
Study 10636973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling intervention
Number of subjects: 813
Study 10636973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention replacing saturated with unsaturated fatty acids
Number of subjects: 813
Study 7495976 — intervention group
Group type: EXPERIMENTAL
Intervention: Octavi S/D
Number of subjects: 0
Study 7495976 — intervention group
Group type: EXPERIMENTAL
Intervention: Octavi S/D+heat treatment
Number of subjects: 0
Study 2317422 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-holed catheter
Number of subjects: 474
Study 2317422 — intervention group
Group type: COMPARATOR
Intervention: Multi-holed catheter
Number of subjects: 474
Study 6244679 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with VM 26 and CCNU once every four weeks, commencing four weeks after the completion of radiotherapy.
Number of subjects: 31
Study 6244679 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 31
Study 31732883 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste (500 ppm, n=50)
Number of subjects: 127
Study 31732883 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP (10% w/v, n=38)
Number of subjects: 127
Study 31732883 — intervention group
Group type: COMPARATOR
Intervention: Combination group (Fluoride then CPP-ACP, n=39)
Number of subjects: 127
Study 30714336 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaco-EX-PRESS P50 with mitomycin C (0.2 mg/ml for 2 min)
Number of subjects: 98
Study 30714336 — intervention group
Group type: COMPARATOR
Intervention: Phaco-NPDS with Esnoper V2000 and mitomycin C (0.2 mg/ml for 2 min)
Number of subjects: 98
Study 28906355 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE and sorafenib
Number of subjects: 72